Compositions and methods for treating primary effusion lymphoma

Patent metadata

Field	Value
Publication number	US-9931332-B2
Application number	US-201514814149-A
Country	US
Kind code	B2
Filing date	Jul 30, 2015
Priority date	Jul 30, 2014
Publication date	Apr 3, 2018
Grant date	Apr 3, 2018

Abstract

Methods for treating primary effusion lymphoma (PEL) are provided. The methods include administering to a patient in need thereof an effective amount of an immunomodulatory compound. Suitable immunomodulatory compounds include compounds having the formula:

wherein X in Formula IV may be independently selected from the group that includes hydrogen, a halide, an aliphatic group and an amine group.

First claim

What is claimed is:

1. A method of treating primary effusion lymphoma (PEL) comprising administering to a patient in need thereof an effective amount of
an immunomodulatory compound selected from the group consisting of

wherein X in Formula IV and Formula V may be independently selected from the group consisting of hydrogen, a halide, an aliphatic group and an amine group; and
a BRD4 inhibitor selected from the group consisting of

2. The method of claim 1 , wherein the immunomodulatory compound and the BRD4 inhibitor are administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

3. The method of claim 1 , wherein the immunomodulatory compound or pharmaceutically acceptable salt thereof is provided as a composition comprising the compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

4. The method of claim 1 , wherein the immunomodulatory compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof are provided as a composition comprising the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

5. The method of claim 1 , wherein the immunomodulatory compound and the BRD4 inhibitor are administered intraperitoneally by infusion or injection.

Assignees

• Chaudhary Preet M
• Gopalakrishnan Ramakrishnan
• Univ Southern California

Inventors

• Chaudhary Preet M
• Gopalakrishnan Ramakrishnan

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/551

  having two nitrogen atoms, e.g. dilazep · CPC title